Welcome to our dedicated page for Acurx Pharmaceuticals SEC filings (Ticker: ACXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acurx Pharmaceuticals, Inc. (ACXP) SEC filings page on Stock Titan aggregates the company’s regulatory documents from the U.S. Securities and Exchange Commission, giving investors a structured way to review its disclosures as a late-stage biopharmaceutical developer of Gram-positive selective DNA polymerase IIIC (pol IIIC) inhibitor antibiotics.
Through this page, users can access registration statements such as Acurx’s Form S-1 filings, which describe the company’s business overview, risk factors, emerging growth company status, and details of financing arrangements including equity lines of credit and warrant inducement transactions. These documents explain how Acurx raises capital to fund its ibezapolstat Phase 3 program and broader DNA pol IIIC pipeline.
Investors can also review current reports on Form 8-K that Acurx files to report material events. Recent 8-K filings describe actions such as a 1-for-20 reverse stock split, amendments to the certificate of incorporation to increase authorized shares, warrant agreements, and Nasdaq compliance developments. These filings provide formal documentation of corporate actions that affect ACXP’s capital structure and listing status.
Proxy materials, including definitive proxy statements (DEF 14A), outline matters submitted to stockholders, such as approval of warrant-related share issuances and authorized share increases. Together with interim and annual financial statements referenced in Acurx’s reports, these filings give insight into operating expenses, research and development spending, and shareholders’ equity for a company advancing late-stage antibiotic candidates.
On Stock Titan, ACXP filings are paired with AI-powered summaries that highlight key points—such as how a reverse stock split changes share counts, or how a new S-1 relates to existing financing agreements—so readers can more quickly interpret lengthy documents while retaining the option to drill down into the full SEC text.
Acurx Pharmaceuticals files its annual report describing progress on ibezapolstat, a first‑in‑class oral antibiotic targeting DNA pol IIIC to treat Clostridioides difficile infection (CDI). Phase 2 trials showed a 96% clinical cure rate in 26 treated patients, with rapid eradication of C. difficile and no drug‑related serious adverse events. Microbiome data suggest ibezapolstat preserves beneficial gut bacteria and may lower recurrence compared with vancomycin. The drug holds FDA Qualified Infectious Disease Product and Fast Track designations, supporting an expedited Phase 3 path. Acurx estimates U.S. CDI incidence approaching 600,000 infections annually and projects potential peak‑year sales over $1 billion if approved, reflecting the significant unmet need for recurrence‑reducing CDI therapies.
Acurx Pharmaceuticals is reducing cash compensation and advancing its lead antibiotic program. Effective April 1, 2026, the Compensation Committee approved fully voluntary 10% base salary cuts for senior executives, including the CEO and Executive Chairman, and a 10% cut to cash retainers for non-employee directors, while equity incentives remain unchanged.
The company also launched a new clinical initiative to expand ibezapolstat into recurrent C. difficile infection with an open-label pilot trial in up to 20 multiply‑recurrent patients, with start-up activities later this month and first-patient enrollment expected in the fourth quarter, intended to inform a planned Phase 3 registration trial and a future FDA LPAD approval request.
Acurx Pharmaceuticals, Inc. is registering up to 750,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under an existing purchase agreement. These shares may be issued to Lincoln Park over a 24‑month period, with Lincoln Park then selling them into the market.
Acurx will not receive proceeds from Lincoln Park’s resales, but may receive up to $7.6 million in aggregate gross proceeds from future sales of stock directly to Lincoln Park under the $12.0 million purchase agreement. As of January 30, 2026, Acurx had 2,546,717 shares outstanding, and operates as a late‑stage biopharmaceutical company developing Gram‑positive‑targeted antibiotics, including for C. difficile and MRSA.
Acurx Pharmaceuticals, Inc. is registering 750,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC under an existing equity purchase agreement. These shares are "Purchase Shares" that have been or may be issued to Lincoln Park under a $12.0 million commitment.
The company is not selling any shares in this prospectus and will not receive proceeds from Lincoln Park’s resales. However, Acurx may still receive up to $7.6 million in gross proceeds from future direct sales of common stock to Lincoln Park under the Purchase Agreement, separate from this resale.
As of January 30, 2026, Acurx had 2,546,717 common shares outstanding. If all 750,000 registered shares were issued, they would represent about 23% of total shares and about 24% of shares held by non-affiliates, increasing dilution for existing stockholders.
Acurx Pharmaceuticals (ACXP) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $1,992,790 and a nine‑month net loss of $6,388,262. Cash was $5,906,802 as of September 30, 2025, with total assets of $6,105,211, liabilities of $2,468,175, and shareholders’ equity of $3,637,036. Operating expenses fell year over year, led by lower R&D ($429,691 vs. $1,198,184 in Q3 2024).
The company completed multiple financings in 2025: a January registered direct offering ($2.5M gross), a March registered direct offering with pre‑funded warrants ($1.1M gross), an equity line of credit with Lincoln Park of up to $12.0M (393,532 shares sold for $2.4M gross through Q3), and a June warrant‑inducement exercise yielding ~$2.5M net. Subsequent to quarter‑end, $1.4M was received from warrant exercises, and total ELOC sales reached 499,999 shares for ~$3.0M gross through November 11, 2025.
The company effected a 1‑for‑20 reverse stock split on August 4, 2025 and increased authorized common shares to 250,000,000 in September. Management disclosed “substantial doubt” about the ability to continue as a going concern. Shares outstanding were 1,800,299 as of September 30, 2025 and 2,085,363 as of November 11, 2025.
Acurx Pharmaceuticals filed a resale prospectus for up to 585,000 shares of common stock to be sold from time to time by Lincoln Park Capital under an existing purchase agreement. The company is not selling any securities in this prospectus and will not receive proceeds from sales by the selling stockholder.
Under the Purchase Agreement, Acurx may sell additional shares to Lincoln Park at its discretion, from which the company may receive up to $9.0 million in aggregate gross proceeds (in addition to $3.0 million previously received), subject to terms and conditions. The selling stockholder is deemed an underwriter, and Acurx will cover registration expenses other than brokerage fees.
A 1-for-20 reverse stock split became effective on August 4, 2025. As of October 14, 2025, 2,081,323 shares were outstanding. If all 585,000 shares registered here were issued and outstanding as of that date, they would represent approximately 22% of total shares outstanding. A 4.99% Beneficial Ownership Cap applies to Lincoln Park, which may be increased to 9.99% upon notice and after 61 days.
Acurx Pharmaceuticals (ACXP) filed an S‑1 to register up to 585,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC. The company is not selling any securities in this prospectus and will not receive proceeds from the selling stockholder’s sales.
These shares relate to Acurx’s May 8, 2025 Purchase Agreement with Lincoln Park. Separately from this resale, Acurx may sell additional shares to Lincoln Park at its discretion and could receive up to $9.0 million in aggregate gross proceeds (in addition to $3.0 million previously received) after the May 29, 2025 commencement, subject to conditions. Regular purchases are priced at 97% of the lower of the day’s lowest sale price or the average of the three lowest closes in the prior 10 business days, with per‑day share and $500,000 per‑purchase caps and optional accelerated purchases. A 4.99% Beneficial Ownership Cap applies, which Lincoln Park may increase to 9.99% with 61 days’ notice. Shares outstanding were 2,081,323 as of October 14, 2025. A 1‑for‑20 reverse stock split became effective on August 4, 2025.
Acurx Pharmaceuticals, Inc. filed a Form 8-K dated September 22, 2025 reporting a material event: the company attached a Certificate of Amendment to the Certificate of Incorporation that is dated September 19, 2025. The filing notes inclusion of the cover page Inline XBRL tags and is signed by David P. Luci, President and Chief Executive Officer. The report appears limited to the corporate charter amendment and related filing mechanics; no financial statements, earnings data, or transaction details are included in the provided text.
Acurx Pharmaceuticals, Inc. stockholders approved several key items at a special meeting held on September 16, 2025. Of 30,524,540 common shares outstanding as of the July 21, 2025 record date, 19,365,579 shares, or about 63.44%, were represented, establishing a quorum. Stockholders approved, for Nasdaq Listing Rule 5635(d) purposes, issuing common shares underlying Series G-2 warrants that could equal 20% or more of common stock outstanding before those warrants were issued. They also approved increasing authorized common shares from 200,000,000 to 250,000,000, subject to the board’s discretion, and approved the potential adjournment of the meeting to solicit additional proxies if needed.
Armistice Capital and Steven Boyd report passive ownership of 8.70% of Acurx Pharmaceuticals common stock. The filing states Armistice Capital, as investment manager of Armistice Capital Master Fund Ltd., and Steven Boyd, as managing member, share voting and dispositive power over 2,917,975 shares. The Master Fund is the direct holder while Armistice Capital exercises investment and voting power under an Investment Management Agreement; the Master Fund disclaims beneficial ownership arising solely from that agreement. The filing is made on Schedule 13G indicating the holdings are reported as passive.